Table 1 Patient characteristics, location of tumours, staging and investigated lymph nodes

From: Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer

Patient No

Sex

Age (year)

Tumour site

Duke's classification

Metastatic nodes/harvest nodes

No of SNs obtained

Number of cells in SN (× 106)

%CD4/%CD8 a

 1

M

80

Sigmoid

B

0/18

1

27

44/6

 2

M

81

Ascending

B

0/22

1

63

52/7

 3

F

58

Ascending

B

0/29

1

MI

41/7

 4

F

80

Ascending

B

0/5

2

29

65/4

 5

M

82

Ascending

B

0/12

4

14

55/14

 6

M

66

Descending

B

0/22

3

66

47/5

 7

F

73

Transversum

B

0/23

4

26

58/7

 8

M

66

Caecum

B

0/19

2

159

35/6

 9

M

71

Descending

B

0/25

3

121

43/10

10

M

70

Sigmoid

C

1/14

2

33

55/8

11

F

78

Ascending

C

2/19

2

11

27/58

12

F

75

Ascending

C

4/23

2

36

37/ND

13

F

63

Sigmoid

C

6/20

3

170

41/7

14

F

57

Sigmoid

C

1/17

2

278

41/14

15

F

61

Sigmoid

D

1/13

3

30

34/6

  1. MI=Missing information.
  2. ND=Not done.
  3. aAverage percentage of CD4+ and CD8+ cells in gated SN lymphocytes measured by flow cytometry. Lymphocytes were defined by gating on forward and side scatter characteristics.